Rebates reduced the growth in Medicare Part D spending for brand-name drugs between 2011 and 2015, but spending for brand-name drugs with rebates still grew by $2 billion over the five-year period, according to a report released last week by the Department of Health and Human Services’ Office of Inspector General. Without rebates, total Part D reimbursement for brand-name drugs would have risen 19% over the period, OIG found. In response to a congressional request, OIG examined 1,510 brand-name drugs with Part D reimbursement and rebates each year over the period.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services finalized a decision to cover acupuncture for Medicare patients with chronic low back pain.
Blog
Tom Nickels, AHA executive vice president, responds to a PhRMA-funded study that attempts to deflect blame for a growing crisis of their own making – the…
Headline
The Medicare Payment Advisory Commission recommended that Congress provide a 2% market-basket update for the hospital inpatient and outpatient prospective…
Headline
Commenting yesterday on the Medicare Payment Advisory Commission’s draft recommendations for 2021, AHA said it supports the recommendation to provide current…
Headline
The Centers for Medicare…
Headline
Hospitals participating in the Medicare Bundled Payment for Care Improvement Program reduced spending for lower extremity joint replacements over three years…